Chu Brugmann

Brussels 19 trials 6 recruiting

19 Registered trials

6 Currently recruiting

Organisation

Chu Brugmann

Location

Brussels, Belgium

Identifier

ORG-100041944

Address

Arthur Van Gehuchtenplein 4, 1020, Belgium

Departments

284014-0302:Hémato-oncologie
Cardiology
Dermatology
Gastro enteroloy department
Gastro-enterology
Gastroenterology
Gynécologie-Obstétrique
Infectiologie
Neurology
Oncology
Ophthalmology
Orthopedic surgery
Psychiatry

Clinical trials at this site (19)

Search interface

Shorter versus longer antibiotic treatment for serious urinary tract infections in men Pending

2025-524703-76-00 Urinary tract infection with systemic involvement (UTI: 5
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting

2022-501007-28-00 Breast Neoplasms 5 2023-04-18
A prospective multicentre single-arm study in adults to evaluate the safety and preliminary efficacy of the autologous 3D osteogenic implant… Recruiting

2024-517762-42-01 recalcitrant lower limb nonunion 7 2018-08-02
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-fibrosis) Recruiting

2023-509912-27-00 Metabolic Dysfunction-Associated Steatotic Liver Diseas 5 2024-11-07
Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LPAPI® on the clearance of high-risk oncogenic HPV genital i… Recruiting

2024-513969-39-00 Human Papillomavirus infection 6 2024-05-09
An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi… Recruiting

2022-501453-36-00 Breast cancer 5 2024-02-23
Efficacy and safety of conventional neoadjuvant therapy versus total neoadjuvant therapy in older patients with locally advanced rectal canc… Recruiting

2023-506703-26-00 locally advanced rectal cancer 5 2024-02-07
A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection Ended

2024-520062-54-00 Chronic Hepatitis D Virus (HDV) Infection 4 2025-07-23
Controlled Interruption of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Infections Ended

2024-511016-25-00 Chronic hepatitis B infection 4 2025-01-15
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System with Ranibizumab in Patients … Ended

2023-507130-24-00 Neovascular age-related macular degeneration (nAMD) 5 2021-10-22
A clinical trial to evaluate the safety and effectiveness of MGL-3196 (resmetirom) in patients with Non-Alcoholic Steatohepatitis (NASH) and… Ended

2024-510626-89-00 Non-Alcoholic Steatohepatitis (NASH) 5 2019-11-18
Study to compare the efficacy and safety of NT 201 (botulinum toxin) with placebo for the treatment of lower limb spasticity caused by strok… Ended

2023-505810-12-00 Lower limb spasticity 5 2019-09-03
A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients with Overt Hepatic Encep… Ended

2025-521029-34-00 Patients with overt hepatic encephalopathy (OHE) and ac 4 2025-09-18
Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization Ended

2024-512651-20-00 Fetal and Neonatal Alloimmune Thrombocytopenia due to H 4 2024-11-20
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) Ended

2022-502899-23-00 Hepatic Encephalopathy (OHE) 5 2024-04-23
A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended

2022-501418-69-00 Acute Coronary Syndrome 5 2023-11-21
A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression. Ended

2023-508163-74-00 Major Depressive Disorder 5 2023-06-12
Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical … Ended

2022-501585-22-00 Atopic Dermatitis 5 2023-05-11